TABLE 1.
Key information of included trials.
| Study | Intervention arm | Control arm | Clinical stage | HR (95%CI) | SAE/Total. (%) | ||
|---|---|---|---|---|---|---|---|
| PFS | OS | Intervention arm | Control arm | ||||
| Keynote407 (Paz-Ares et al., 2020) | Pembrolizumb + chemotherapy | chemotherapy | Ⅳ | 0.57 (0.47–0.69) | 0.71 (0.58–0.88) | 206/278 (74) | 195/290 (70) |
| Impower 131 (Jotte et al., 2020) | Atezolizumab + chemotherapy | chemotherapy | Ⅳ | 0.71 (0.60–0.85) | 0.88 (0.73–1.05) | 277/334 (83) | 235/334 (70) |
| Orient12 (Zhou et al., 2021) | Sintilimab + chemotherapy | chemotherapy | ⅢB-Ⅳ | 0.536 (0.422–0.681) | 0.567 (0.353–0.909) | 155/179 (87) | 148/178 (82) |
| CAMEL-sq (Zhou et al., 2021) | Camrelizumb + chemotherapy | chemotherapy | Ⅳ | 0.37 (0.29–0.47) | 0.55 (0.4–0.75) | 142/193 (74) | 141/196 (72) |
| Rationale307 (Wang et al., 2021) | Tislelizumab + chemotherapy | chemotherapy | ⅢB-Ⅳ | 0.52 (0.37–0.74) | NA | 106/120 (88) | 98/117 (84) |
| Gemstone302 (Zhou et al., 2022) | Sugemalimab + chemotherapy | chemotherapy | Ⅳ | 0.34 (0.24–0.48) | 0.48 (0.31–0.74) | 205/320 (64) | 98/159 (62) |
| CHOICE-01 (Wang et al., 2021) | Toripalimab + chemotherapy | chemotherapy | Ⅳ | 0.55 (0.38–0.83) | NA*: | NA | NA |
HR, hazard ratios; OS, overall survival; PFS, progression-free survival; SAE, severe adverse events.* The HR reported by the study does not subdivide sq and nsq.